Clinical research
We believe that any form of supplementation you put in your body should be based on clinical research and proven results, which is why KPAX has undergone rigorous research and clinical testing since 2004.
We know that mitochondria – the powerhouse of our cells – plays a critical role in regulating autoimmune disorders and neurodegenerative diseases. We also understand that well-functioning mitochondria supports everyday vitality and long-term longevity. We invite you to view the published clinical trials based on our mitochondrial support formulas below.
Studies
2019
“Treatment for Gulf War Illness (GWI) with KPAX002 (methylphenidate + GWI nutrient formula) in subjects meeting the Kansas case definition: A prospective, open-label trial”
(J Psychiatr Res 2019;Volume 118:14-20)
The results of this study concluded that KPAX002 (methylphenidate plus K-PAX Immune) was associated with a significant decrease in multiple GWI symptoms.
At 12 weeks, subjects taking this treatment experienced a mean 25% reduction in their overall GWI symptoms severity (as measured by the GWI Symptoms Assessment Tool (SAT) (p < 0.001). Significant improvements were also observed in fatigue, cognitive symptoms, sleep problems and pain.
2018
“KPAX002 as a Treatment for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS): a Prospective, Randomized Trial”
(Int J Clin Exp Med 2018;11(3):2890-2900)
The results of this study concluded that KPAX002 (methylphenidate plus KPAX002 (methylphenidate plus K-PAX Immune) demonstrated improvement in fatigue and concentration disturbance symptoms in multiple analyses. Two key subgroups of patients whose responses approached statistical significance were identified. These included study subjects with more severe symptoms and patients with both fatigue and pain.
The K-PAX Energy Support Program is an over-the-counter version of this same concept. It consists of the same mitochondrial support nutrients plus a low dosage of caffeine (instead of Ritalin®) and is designed to help increase energy and mental alertness.
2015
“A Prospective, Proof-of-concept Investigation of KPAX002 in Chronic Fatigue Syndrome (CFS)”
(Int J Clin Exp Med 2015;8(7):11064-11074)
The results of this clinical trial showed that treatment with KPAX002 (methylphenidate plus K-PAX Immune) improved overall Chronic Fatigue Syndrome symptoms by 34% at 12 weeks as measured by the Checklist Individual Strength (CIS) total score. This represented a >25% improvement in 87% of the participants. Treatment with KPAX002 was well tolerated and significant improvement in fatigue occurred in over 50% of CFS subjects.
The K-PAX Energy Support Program is an over-the-counter version of this same concept. It consists of the same mitochondrial support nutrients plus a low dosage of caffeine (instead of Ritalin®) and is designed to help increase energy and mental alertness.
2006
“Micronutrient Supplementation Increases CD4 Count in HIV-infected Individuals on HAART: A Prospective, Double-Blinded, Placebo-Controlled Trial”
(JAIDS 2006;42(5):523-528)
The results of this study concluded that the micronutrient formula tested (the prototype of K-PAX Immune) significantly improved CD4 cell count reconstitution in HIV-infected patients taking HAART. The intervention was well-tolerated and appears to be safe when combined with antiretroviral therapy.